Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Safe Supply Announces Proposed Acquisition of European Medical Testing Subsidiary (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News FibroGen Inc FGEN

Healthcare Biotechnology
FibroGen, Inc. is a biopharmaceutical company. The Company is engaged in developing and commercializing a diversified pipeline of novel therapeutics that work at the frontiers of cancer biology and anemia. Its clinical, commercial, and research programs include Pamrevlumab, which is a first-in-class antibody being developed by FibroGen to inhibit the activity of connective tissue growth factor ... see more

Recent & Breaking News (NDAQ:FGEN)

Kessler Topaz Meltzer & Check, LLP: Securities Fraud Class Action Filed Against FibroGen, Inc.

GlobeNewswire May 3, 2021

SHAREHOLDER ACTION ALERT: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against FibroGen, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

Newsfile May 3, 2021

FGEN NOTICE: ROSEN, TOP RANKED INVESTOR COUNSEL, Encourages FibroGen, Inc. Investors with Losses to Secure Counsel Before Important Deadline - FGEN

ACCESSWIRE IA May 3, 2021

FibroGen to Report First Quarter 2021 Financial Results

GlobeNewswire May 3, 2021

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of FibroGen, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of June 11, 2021 - FGEN

Newsfile May 3, 2021

Pomerantz Law Firm Announces the Filing of a Class Action Against FibroGen, Inc. and Certain Officers - FGEN

PR Newswire May 1, 2021

FibroGen, Inc. Reminder: Kessler Topaz Meltzer & Check, LLP Reminds Investors of Securities Fraud Class Action Lawsuit Filed Against FibroGen, Inc.

ACCESSWIRE IA May 1, 2021

FibroGen Update

Newsfile May 1, 2021

SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KSF REMINDS DOX, FGEN, GOEV, WKHS INVESTORS of Lead Plaintiff Deadline in Class Action Lawsuits

GlobeNewswire April 30, 2021

Important Investor Reminder: Kessler Topaz Meltzer & Check, LLP Reminds FibroGen, Inc. Investors of Deadline in Securities Fraud Class Action Lawsuit

PR Newswire April 30, 2021

HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Updates ACAD, FGEN, RMO Investors on Securities Class Actions and Application Deadlines, Encourages Investors with Losses to Contact the Firm

ACCESSWIRE IA April 30, 2021

JUNE 11 2021 FGEN INVESTOR FILING DEADLINE: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Fibrogen Inc.

Newsfile April 30, 2021

FIBROGEN SHAREHOLDERS: June 11, 2021 Filing Deadline in Class Action - Contact Lieff Cabraser

Business Wire April 30, 2021

SHAREHOLDER ACTION ALERT: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against FibroGen, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

ACCESSWIRE IA April 30, 2021

FIBROGEN SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, Llc Reminds Investors with Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Fibrogen, Inc. - FGEN

Newsfile April 29, 2021

FGEN CLASS ACTION DEADLINE: HAGENS BERMAN, National Trial Attorneys, Reminds FibroGen (FGEN) Investors of Securities Fraud Lawsuit, Advises Investors with Losses to Contact Its Attorneys Now

Newsfile April 29, 2021

ROSEN, A GLOBAL AND LEADING LAW FIRM, Encourages FibroGen, Inc. Investors with Losses Exceeding $100K to Secure Counsel Before Important Deadline - FGEN

GlobeNewswire April 29, 2021

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of FibroGen, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of June 11, 2021 - FGEN

Newsfile April 29, 2021

Kessler Topaz Meltzer & Check, LLP Announces Investor Securities Fraud Class Action Lawsuit Filed Against FibroGen, Inc. (FGEN)

GlobeNewswire April 29, 2021

INVESTOR ACTION NOTICE: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against FibroGen, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

ACCESSWIRE IA April 29, 2021